Manuel Sardo

Sandoz, recently spun-off from parent Novartis, is a Global leader in Biosimilars, Specialty pharmaceutical and Generic medicines with over $10Bn in annual sales worldwide. Our mission is to deliver affordable innovative medicines to increase patient access to life changing therapies. This is a critical role tasked with leading efforts in researching, structuring, negotiating, and securing licensing and bolt-on acquisition transactions in the Biosimilars, Generic and OTC space that enhance top line revenue and profitability for both the US and Global pipeline. -Streamlined deal process, evaluations, technical Due Diligence, modeling, negotiations and governance to improve deal flow, significantly reduce cycle time and close multiple deals simultaneously.

Ovid is a clinical-stage biotechnology company focused on the discovery and development of novel compounds and gene therapies for the treatment of rare CNS disorders. Assumed leadership of strategic assessments of a novel mechanism of action for the treatment of rare CNS diseases and established Academic Discovery and Industry collaborations for disease-modifying Genetic therapies. • Defined and established BD roadmap aligned with corporate strategic imperatives • Guided a team of talented Neuroscience PhD’s and BD professionals, focusing efforts to deliver on near-term transformational transactions. • Negotiated and closed in-licensing and academic collaborations for resistant epilepsies

Pacira is a global leader delivering non-opioid pain management pharmaceutical and regenerative medicine solutions, including Medical devices focused on CNS (Pain and Analgesia), Osteoarthritis and musculoskeletal areas. Primarily responsible for the leadership of strategic assessments of novel, competitive and potentially synergistic therapeutic compounds, medical devices and digital health/therapeutics initiatives. Advise leadership and drive inorganic growth via venture investing, out/in licensing and strategic partnerships.

Responsible for corporate growth initiatives via licensing and new distribution partnerships for the companies’ vaccines portfolio, including search and evaluation of new products, novel delivery technologies and strategically aligned adjacencies to Flu Vaccine portfolio. Member of Latam and EMEA Regional Leadership team, working to expand government relationships to access markets.

BAYER ACQUIRED MERCK CONSUMER (OCT. 2014) Drive corporate growth via search and evaluation, in/out-licensing, mergers & acquisitions, strategic partnerships and alliance management of products/companies/technologies to support Consumer divisional and Dermatology Rx BU global expansion strategy. Drafted and negotiated complex deal terms and legal documents and provided guidance on financial and legal topics. Led and coached senior team of 6 accomplished professionals located in the US, Europe and China. •Defined and implemented Active Portfolio Management strategy and executed on M&A and Divestitures aligned to strategy •Restructured full team; reorganized/hired top performers delivering commitments and optimizing deal flow

Recruited by SVP BD&L to lead BD&L efforts to drive corporate development; including, search and evaluation, in/out-licensing and M&A Transactions, strategic partnerships and Alliance management of products/companies/technologies to support Divisional global expansion strategy. •Managed and closed multiple strategic transactions across all geographies delivering ongoing Gross Sales of over $1Bn+ USD •Collaborated on defining divisional strategy, setting targets and executed M&A and Licensing transactions aligned with agreed strategy •Drafted and negotiate key legal documents and provide guidance to management on topics of relative legal significance

Recruited by SVP BD&L to visible role leading the search, evaluation, structuring and negotiating of external transactions, including in-licensing, divestitures, acquisitions, joint development and strategic alliances to expand Global business pipeline. •Extensive interaction with Banking, Private Equity, and VC community unlock strategic opportunities •Searched, evaluated and executed numerous multi-million Global strategic Licensing transactions

Selected to newly created key role accountable for global/market strategic planning, budgeting and forecasting; working closely with BU/Region leaders to prepare financial and valuation/economic analysis to drive strategic and operational decision making. Financial performance reporting and overall management of the budget for the Business Unit and Category teams. •Change management and process enhancement initiatives, eliminating non-value-added investments and efforts •Managed over $800M in divisional marketing, media, trade promotion, sales and G&A budgets •Built strong relationships and partnered with corporate stakeholders to create critical processes and data analysis procedures •Successfully re-negotiated Global Media Agency contracts resulting in over $3M in annual cost savings •Review and/or develop P&L’s, NPV analyses, and test sensitivity of initiative economics to key assumptions and deal terms •Led Divisional monthly close process with entire P&L responsibility and direct accounting entries •Led Strategic Planning, 5YR target setting, forecasting and management reporting processes •Manage Divisional budgets and Brand P&L’s, contingency planning ensuring adequate profit protection

Recruited to define and implement a new and efficient divisional sales forecasting and opportunity tracking process. Operating in a complex matrixed environment, improved quality, efficiency, accuracy of analytical support and sales forecasting to deliver timely line of sight and relevant mitigation recommendations to NA Executive Board on weekly basis.

Recruited by CFO to develop and implement a robust RFP Global pricing, contract policies and metrics to facilitate deal negotiations of proprietary CRM/Salesforce software, development and consulting services focused on the Pharma, Biotech, Consumer and FMCG industries. Lead financial terms and negotiations to close a major deal, increasing annual company revenues by +35%. Provided guidance and leadership to Executive management on financial analysis metrics and strategic plan development achieving operational improvements.

ADMITTED New Jersey - 2007 New York - 2008 US District Court New Jersey - 2007